TY - JOUR AU - Galvez, Kenny PY - 2019/02/04 Y2 - 2024/03/28 TI - Efficacy of Generic Bortezomib Used as a Part of CyBorD Regimen to Achieve Complete Response in Multiple Myeloma JF - Innovative Journal of Medical and Health Sciences JA - ijmhs VL - 9 IS - 1 SE - Research Articles DO - 10.15520/ijmhs.v9i1.2431 UR - http://innovativejournal.in/index.php/ijmhs/article/view/2431 SP - 247-251 AB - <p>Bortezomib is a preferred yet costly drug in multiple myeloma (MM) treatment. Thus, despite its benefits, bortezomib is substituted with cheaper options like thalidomide; sometimes compromising the efficacy of treatment. This case report of a 53-year old transplantation eligible MM patient from Colombia shows that substituting branded bortezomib with its generic version in the bortezomib, cyclophosphamide and dexamethasone (CyBorD) regimen can also help in complete remission. This case provides evidence that high quality generic drug is as safe and efficacious as the innovator product. Improving awareness about clinical and cost saving benefits of generic medications in oncology practices could make cancer treatment affordable for many patients in lower and middle-income countries (LMIC) like Colombia. Clinical usage of generic drugs similar to that of their branded/innovator counterparts is the need of the hour. Adequate policies along with transparent and ethical promotions must be implemented to ensure maintenance of high quality care at an affordable cost.</p> ER -